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QM/MM simulations as an assay for
carbapenemase activity in class A b-lactamases†
Ewa I. Chudyk,a Michael A. L. Limb,a Charlotte Jones,a James Spencer,b
Marc W. van der Kamp*a and Adrian J. Mulholland*a
Carbapenems, ‘last resort’ antibiotics for many bacterial infections, can
now be broken down by several class A b-lactamases (i.e. carbapene-
mases). Here, carbapenemase activity is predicted through QM/MM
dynamics simulations of acyl–enzyme deacylation, requiring only the
3D structure of the apo-enzyme. Thismay assist in anticipating resistance
and future antibiotic design.
Antibiotic (antimicrobial) resistance, particularly in Gram-negative
bacteria such as Escherichia coli and Pseudomonas aeruginosa,1 has
emerged as an extremely serious and growing medical problem. It
threatens modern medicine, not only due to the growing diﬃculty
of treating bacterial infections, but also jeopardizing many thera-
pies and surgical procedures.2 Much of the developing resistance in
such bacteria can be attributed to b-lactamases, enzymes which
catalyse the breakdown of the essential b-lactam ring present in all
classes of b-lactam antibiotics.3 Carbapenems are a highly potent
class of antibiotics: they have a broad spectrum of antibacterial
activity and, in contrast to many other classes of antibiotic, have not
been susceptible to resistance due to hydrolysis by b-lactamases.
The characteristic broad-spectrum antibacterial activity exhibited by
carbapenems means that they are currently used as eﬀective treat-
ments for otherwise incurable bacterial infections.4
Alarmingly, however, a variety of carbapenem-hydrolysing
b-lactamases have been reported5 and are becoming increasingly
common. These b-lactamases, known as carbapenemases, are able
to eﬃciently hydrolyse the b-lactam ring in carbapenems, rendering
this formerly highly potent class of antibiotics inactive and resulting
in the re-emergence of potentially untreatable bacterial infections.6
The most common enzymes with carbapenemase activity are
b-lactamases of class A (exemplified by the SFC-1 andKPC-2 enzymes7)
and class D. Class B b-lactamases, such as NDM-1, are also
increasingly prevalent carbapenemases.8 Here, we focus on
b-lactamases of class A due to the growing frequency with which
carbapenem-hydrolysing enzymes are encountered in both clinical
and environmental bacteria. Carbapenemase activity in these
enzymes is due to eﬃcient deacylation; the majority of class A
enzymes are inhibited by carbapenems because a long-lived acyl–
enzyme complex is formed.
The first step of the class A b-lactamase hydrolysismechanism is
formation of an acyl–enzyme intermediate (via nucleophilic attack
by an active site serine), with coincident opening of the b-lactam
ring.9 Deacylation is then required to release the cleaved b-lactam
and allow enzyme turnover. Deacylation is initiated by nucleophilic
attack of a conserved water molecule (the deacylating water mole-
cule, DW) on the ester carbon of the acyl–enzyme (Fig. 1). The water
molecule is activated by proton abstraction by a glutamate residue
situated in the active site acting as a base.10
Carbapenem-inhibited class A b-lactamases are acylated readily
but have a greatly reduced rate of deacylation,11 resulting in a long-
lived acyl–enzyme. In contrast, b-lactamases with carbapenemase
activity deacylate efficiently (with a short-lived acyl–enzyme), confer-
ring carbapenem resistance on bacteria that carry these enzymes.
Despite multiple structural12,13 and biochemical studies14,15 on class
A b-lactamases, the difference in carbapenemase activity exhibited by
different b-lactamases (which have highly homologous active sites) is
not well understood. Recently, we suggested that the orientation of
the 6a-1R-hydroxyethyl group of carbapenems in the enzyme
Fig. 1 The first step of carbapenem deacylation: the acyl–enzyme (A) reacts
to form a tetrahedral intermediate (B) (numbering for the TEM-1 enzyme).10
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active site may have an important influence on the deacylation
rate (based on crystal structures and molecular dynamics (MD)
simulations of the carbapenemase SFC-1).7 We proposed that,
in carbapenemases, a conformation of the 6a-1R-hydroxyethyl
that does not interfere with the nucleophilic attack of the DW is
favored, which facilitates deacylation. Further subtle structural
differences were identified that may affect the rate of deacylation,
supporting previous findings.14,16,17 Here we use simulations to
investigate class A b-lactamases, with the aim of identifying
determinants of carbapenemase activity, and ultimately of applying
these principles to assess the ability of uncharacterized enzymes to
hydrolyse carbapenems. The need to recognize new and emerging
resistance threats is growing in importance as new enzymes
continue to be identified and new sequences emerge from
large-scale sequencing projects.
We employ hybrid quantummechanics/molecular mechanics
(QM/MM) umbrella sampling MD calculations to investigate
carbapenem hydrolysis in class A b-lactamases.18 Because the
diﬀerence between carbapenemases and carbapenem-inhibited
enzymes is in the deacylation step, and tetrahedral intermediate
(TI) formation is likely to have the highest barrier in this
reaction,11 we model the first step of deacylation only (Fig. 1).
Simulations were performed with the semi-empirical SCC-DFTB
QM method19 in the AMBER12 simulation package,20 using the
ﬀ12SB MM force-field for the protein, the TIP4P-Ew water model
and the General AMBER Force Field (GAFF) for the part of
meropenem not in the QM region. The QM region (Fig. S1, ESI†)
consisted of the common carbapenem scaﬀold (omitting the
3-[5-(dimethylcarbamoyl) pyrrolidin-2-y]-sulfanyl R-group when
modelling meropenem, see Fig. 1), DW and the Ser70 and
Glu166 sidechains from Cb. The protocol can be summarized
as follows (see ESI† for details):
(1) Generate and solvate the acyl–enzyme complex (AC) starting
structure. In absence of an acyl–enzyme crystal structure, dock
meropenem into the protein in the conformation observed crystallo-
graphically in the SFC-1 acyl–enzyme (PDB ID: 4EV4).
(2) Heat the system to 300 K and equilibrate at 300 K and
1 atm in QM/MM MD (see ESI†).
(3) 300 ps of unrestrained QM/MM MD of the acyl–enzyme.
(4) Select a starting structure for reaction modelling. Previous
work7 indicated that three distinct conformations of the 6a-1R-
hydroxyethyl group could be present in the acyl–enzyme
complex. A suitable structure for reaction modelling must satisfy
two criteria: (i) it contains the predominant conformation of the
6a-1R-hydroxyethyl observed over the course of 300 ps unrestrained
MD simulation and (ii) it contains the DW correctly positioned
for nucleophilic attack of the electrophilic carbon in the ligand
(indicated by a distance of less than 3.5 Å). If both cannot be
satisfied, steps 1–3 are repeated with the 6a-1R-hydroxyethyl
conformation as in the structure with PDB ID: 4EUZ.7
(5) Perform QM/MM umbrella sampling MD along two reaction
coordinates: rx = d(Oe1Glu166–H2DW)  d(H2DW–ODW) (proton trans-
fer from DW to Glu166) and ry = d(CCMer–ODW) (nucleophilic attack
of DW on the carbonyl carbon) to simulate the deacylation reaction.
Perform 20 ps of MD for each simulation window. We repeated this
step three times to test convergence.
(6) Calculate the 2D free energy surface for the reaction
using the weighted-histogram analysis method (WHAM) and
identify the minimum energy path (MEP) on this surface; the
highest point along the MEP is taken as the transition state,
giving the activation free energy, DG‡calc (Fig. 2).
The carbapenemase activity of eight diﬀerent class A b-lactamases
was assessed using this simulation assay: these were the carbapene-
mases KPC-2, NMC-A, SFC-1 and SME-1 and the carbapenem-
inhibited b-lactamases CTX-M-16, BlaC, TEM-1, and SHV-1.
Additionally, the deacylation of benzylpenicillin in TEM-1 was
simulated for comparison and to investigate the generality of the
method with diﬀerent b-lactam antibiotics. Crystallographic
carbapenem acyl–enzyme structures of wild-type TEM-1, SHV-1
and BlaC and a SFC-1 mutant (E166A), and TEM-1 with benzyl-
penicillin were available. For KPC-2, SME-1, NMC-A and CTX-M-
16, the crystal structure of the apo-form was used as the starting
point (see Table S1, ESI†). For all eight enzymes, experimental
kinetic data are available, enabling comparison of the calculated
barriers with experiment (Table 1).
The results indicate that the protocol demonstrated here
correctly distinguishes carbapenemases from carbapenem-
inhibited class A b-lactamases. A low calculated activation free
energy of B10 kcal mol1 signifies eﬃcient deacylation (and
therefore carbapenemase activity) whereas higher calculated
activation free energies of 17–18 kcal mol1 show a long-lived
acyl–enzyme (and therefore a carbapenem-inhibited enzyme).
This is true both for simulations run from experimentally
determined acyl–enzyme structures and for those with only a
crystal structure of the apo enzyme as input.
In both cases, comparison with experimental data (Table 1;
Fig. 3) reveals a clear discrimination between the two types of
enzyme. Moreover, application to the reaction of TEM-1 with
benzylpenicillin indicates that the same protocol can also
predict activity against other classes of antibiotics.
Fig. 2 Free energy surface for the deacylation of meropenem in KPC-2.
AC: acyl–enzyme complex; TS: transition state; TI: tetrahedral intermediate.
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Comparison of the experimental and calculated barriers
indicates that the SCC-DFTB/AMBER12SB QM/MM method
underestimates the free activation energy, by 6.6 kcal mol1 on
average for carbapenemases, and 4.1 kcal mol1 on average for
the carbapenem-inhibited enzymes. This is due to the SCC-DFTB
method, which is known to underestimate barriers in many
cases.19,25 The QM/MM MD simulations with SCC-DFTB clearly
distinguish between the two enzyme groups. They are computa-
tionally aﬀordable, in contrast to equivalent simulations with
DFT or ab initio methods for the QM region (these methods are
more suitable for e.g. establishing reaction mechanisms9,10). For
the purpose of screening enzyme activity relatively rapidly, semi-
empirical methods (validated for the reaction of interest) thus
remain highly attractive due to their low computational cost.
A vitally important question is understanding themolecular basis
for carbapenemase activity in class A b-lactamases. Common struc-
tural and mechanistic features that diﬀerentiate carbapenemases
from carbapenem-inhibited enzymes have not been identified. Many
features, including active site volume13 and mobility, the propensity
of the carbapenem acyl–enzyme to tautomerise into the less active
D1-pyrroline form,26 the orientation of the carbapenem 6a-1R-
hydroxymethyl group7,27 and the hydrogen bonding pattern of the
deacylating water molecule,16 have been suggested to contribute to
efficient carbapenem hydrolysis. Our simulations show no obvious
common feature determining carbapenemase activity. Instead, mul-
tiple subtle factors appear to be at play, stressing the need for
detailed investigations of individual reactions. Consistent with the
conclusion that multiple subtle effects discriminate class A beta-
lactamases that are carbapenemases from those that are not,
inspection of our simulations suggests different effects in the
different enzymes. For example, we have previously suggested that
one important factor could be the orientation of the 6a-1R-
hydroxymethyl group: when the hydroxyl forms a hydrogen bond
with the deacylating water, the nucleophilic attack of this water on
the acyl–enzyme carbonyl is hampered.7 Although this interaction is
indeed observed in the simulations of one of the carbapenem-
inhibited enzymes (TEM-1), it is not for the others. Additional
simulations and analysis will be required to dissect the subtle
differences in interactions that define the catalytic properties of
the different individual enzymes. The data presented here demon-
strate that the first-principles QM/MM reaction simulations per-
formed here are able to incorporate these multiple relevant subtle
effects, as demonstrated by the ability to predict the deacylation
activity of the multiple systems under investigation. Indeed, detailed
investigation of reactivity (and not e.g. simply studies of acyl–enzyme
dynamics) will probably be necessary to understand the origins of
carbapenemase activity.
In conclusion, the results of our reaction simulations of eight
diﬀerent class A b-lactamases show that QM/MM activation free
energies for formation of the TI in carbapenem deacylation,
obtained using a standard protocol involving semi-empirical QM/
MM MD simulations, correctly predict their carbapenemase activity
in silico. The QM/MM protocol presented here thus provides a
computational assay to predict carbapenemase activity, based on
only the 3D structure of class A b-lactamases. QM/MM simulations
can thus play a vital role in the assessment and understanding of
emerging b-lactam resistance and are potentially useful in the
development of new antibiotics.
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thanks EPSRC & SCI. JS thanks the U.K. Medical Research Council
(MRC; U.K.-Canada Team Grant G1100135) and the U.S. National
Institutes of Health (1R01AI100560-01). This work was conducted
using the computational facilities of the Advanced Computing
Research Centre, University of Bristol.
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